Tumor-Targeting NIR Dye Conjugates With Site-Activated Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for targeted cancer therapeutic agents with maximal efficacy in treating or killing tumor cells and minimal toxicity toward non-tumor or 'normal' cells.
Innovation Solution
The use of tumor-targeting near-infrared (NIR) dyes conjugated to therapeutic agents via linkers to direct the conjugate specifically to target tumor cells, utilizing pH-sensitive, enzyme-sensitive, and self-immolative linkers to release the therapeutic agent only at the tumor site, thereby minimizing adverse effects on normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic agents are used to treat cancer, then they can kill tumor cells, but they also cause significant toxicity to normal cells
Solution Approach 1:
The therapeutic system is segmented into distinct functional components: a tumor-targeting NIR dye moiety, a linker, and a therapeutic agent. This segmentation allows the targeting function to be separated from the therapeutic function, enabling selective delivery to tumor cells while sparing normal cells from direct exposure to the therapeutic agent's toxic effects
Solution Approach 2:
The NIR dye-conjugate acts as an intermediary vehicle that selectively transports the therapeutic agent to tumor cells. The dye portion provides tumor-specific targeting capabilities, while the conjugate structure mediates the delivery of the therapeutic payload, ensuring that the toxic agent only contacts tumor cells and not normal cells
2Reliability
If therapeutic agents are delivered systemically to ensure tumor coverage, then all tumor cells can be reached, but the therapeutic agent cannot be selectively activated at the tumor site
Solution Approach 1:
The conjugate exhibits different properties in different locations: in circulation, it remains stable and inactive, but upon reaching the tumor microenvironment, it undergoes selective activation through linker cleavage. This local quality change allows the system to maintain stability during transport while enabling selective therapeutic activation only at the tumor site
Solution Approach 2:
The conjugate system transitions from a stable, inactive state during systemic circulation to an active therapeutic state at the tumor site. The dynamic behavior is controlled by the linker's response to tumor-specific conditions (pH, enzymes), allowing the system to adapt its state based on location and enabling selective activation only where needed
3Ease of operation
If non-targeted therapeutic agents are used, then they can be administered easily, but they cannot provide real-time monitoring of tumor targeting
Solution Approach 1:
The NIR dye-conjugate performs multiple functions simultaneously: it serves as a tumor-targeting delivery vehicle, a real-time imaging agent for monitoring conjugate distribution and tumor accumulation, and a trigger for therapeutic activation. This multi-functionality eliminates the need for separate monitoring systems while maintaining ease of administration through a single conjugate formulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the efficacy of cancer treatment by selectively targeting tumor cells while reducing toxicity to normal cells, enabling real-time monitoring and imaging through NIR light absorption and emission, and improving the pharmacokinetics of the therapeutic agents.
Implementation Method 1
the present dye can absorb NIR light and emit in the same region with appreciable brightness for corresponding detection and imaging/visualization of tumor location
Data Source
AI summary
A conjugate including a tumor-targeting NIR dye coupled to a therapeutic agent via a linker, whereby the dye functions to direct the conjugate and correspondingly, the therapeutic agent, to a target tumor cell population. Additionally, a method of killing tumor cells by directing a conjugate including a tumor-targeting NIR dye coupled to a therapeutic agent via a linker to a target tumor cell population.